The Food and Drug Administration yesterday approved the first continuous glucose monitoring system with a fully implantable sensor, designed to measure glucose levels in adults with diabetes for up to 90 days. Once implanted under the skin during an outpatient procedure, the sensor sends information to a mobile app to alert users if glucose levels are too high or too low. “The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Friday finalized changes to the Medicare Advantage and prescription drug programs for contract year 2020.
Headline
The AHA today shared with House and Senate members of the Congressional Telehealth Caucus recommendations for improving and expanding access to telehealth. 
Headline
The AHA and the National Quality Forum today released a guide to help hospitals and health systems working to deliver innovative, high-quality telebehavioral…
Headline
The Centers for Medicare & Medicaid Services will host a March 5 listening session on its proposed rule to promote electronic health information exchange.
Headline
The Senate Health, Education, Labor & Pensions Committee today held a hearing to examine how primary care affects health care costs and outcomes.
Insights and Analysis
Grand Rapids, Mich.-based Spectrum Health makes remote consultations available via mobile carts in 34 medical specialties, and Columbus (Neb.) Community…